Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00001418
Other study ID # 940186
Secondary ID 94-N-0186
Status Completed
Phase N/A
First received November 3, 1999
Last updated March 3, 2008
Start date July 1994
Est. completion date August 2004

Study information

Verified date August 2004
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

This study is designed to use PET scans in order to measure activity of the sympathetic nervous system. The sympathetic nervous system is the portion of the nervous system that maintains a normal supply of blood and fuel to organs during stressful situations.

PET scan or Positron Emission Tomography is an advanced form of an X-ray. It is used to detect radioactive substances in the body. During this study researchers plan to inject small amounts of the radioactive drug fluorodopamine into patients. Fluorodopamine is very similar to the chemicals found in the sympathetic nervous system. It can attach to sympathetic nerve endings and allow researchers to view them with the aid of a PET scan. One area of the body with many sympathetic nerve endings is the heart. After giving a dose of fluorodopamine, researchers will be able to visualize all of the sympathetic nerve endings involved in the activity of the heart. In addition, this diagnostic test will help researchers detect abnormalities of the nervous system of patient's hearts.


Description:

This project applies positron emission tomographic (PET) scanning after administration of 6-[18F]fluorodopamine ([18F]-6F-DA) to visualize sympathetic innervation and function in patients with neurocardiologic disorders. Patients undergo infusion of [18F]-6F-DA, followed by PET scanning of one or more body regions. Patients may also undergo PET scanning after administration of [13N]-ammonia, to assess regional perfusion; regional blood sampling (including sampling from the coronary sinus or great cardiac vein) during infusion of [3H]-l-norepinephrine ([3H]-NE), to assess the kinetics and metabolism of NE; or magnetic resonance imaging (MRI) to delineate the ventricular myocardium. PET scanning after [18F]-6F-DA administration, in conjunction with other clinical assessment tools, should provide comprehensive information about regional sympathoneural innervation and function in neurocardiologic disorders.


Recruitment information / eligibility

Status Completed
Enrollment 335
Est. completion date August 2004
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group N/A and older
Eligibility INCLUSION CRITERIA:

The subjects are adult patients in one of the following diagnostic categories: coronary heart disease or chest pain and normal coronary arteries; myocardial dysfunction or failure; hypertension; or dysautonomia. Groups of appropriately matched healthy volunteers are studied concurrently as controls.

EXCLUSION CRITERIA:

Minors are excluded.

Subjects in whom anatomic factors complicate vascular access are excluded.

Subjects who are not expected clinically to tolerate recumbency during the procedures are excluded.

Pregnant or lactating women are excluded.

Cardiology patients may be tested while off their usual medications. In this situation, the patients will be inpatients on the cardiology ward, managed clinically by staff of the Cardiology Branch, DIR, NHLBI. Hypertensives will be tested afer having discontinued anti-hypertensive medications for up to two weeks.

Patients who must take medications continually in the following categories are excluded: anticoagulants, tricyclic antidepressants, barbiturates, aspirin, acetaminophen.

Patients unable to discontinue nicotine or alcohol temporarily are excluded.

Study Design

N/A


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Institute of Neurological Disorders and Stroke (NINDS) Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Recruiting NCT05004857 - The Effect of Reading Therapy on Newborns N/A
Terminated NCT00547911 - Augmenting Effects of L-DOPS With Carbidopa and Entacapone Phase 1/Phase 2
Completed NCT03327493 - Impact of Adrenoreceptor Expressions on Inflammatory Pattern in Refractory Cardiogenic Shock Under VA ECMO N/A
Recruiting NCT05239065 - Personalized Stress Management With Application of Portable Devices in Occupational Populations N/A
Completed NCT03064256 - Aerobic Physical Training and Heart Rate Variability in Hypertersion N/A
Completed NCT02594488 - Implantable Cardiac Monitors in High-Risk Post-Infarction Patients With Cardiac Autonomic Dysfunction N/A
Completed NCT00775853 - Biomarkers of Risk of Parkinson Disease
Recruiting NCT03426085 - The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes Phase 2
Completed NCT03322904 - Sympathetic-parasympathetic Ratio of Our Gaze N/A
Terminated NCT02963181 - Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension Early Phase 1
Not yet recruiting NCT02365974 - Transcutaneous Electrical Nerve Stimulation (TENS) on Arterial Stiffness and Blood Pressure N/A
Not yet recruiting NCT06236945 - HUTT to Assess Cardiac Autonomic Nervous Function
Completed NCT02397681 - Autonomic Responses During the Valsalva Maneuver and Deep Breathing Test Depend on the Experimental Setup N/A
Completed NCT02584712 - Effect of Exercise Training in Autonomic Modulation in Breast Cancer Patients N/A
Recruiting NCT00422474 - Prognostic Significance of the Baroreflex Sensitivity Changes After Acute Ischemic Stroke N/A
Terminated NCT00581477 - Treatment of Orthostatic Hypotension Phase 2/Phase 3
Enrolling by invitation NCT02725060 - Autoimmune Basis for Postural Tachycardia Syndrome N/A
Completed NCT00748059 - The Pathophysiology of Orthostatic Hypotension Phase 1
Completed NCT02830022 - Sleep, Autonomic Nervous System and Cardiorespiratory Capacity in Autism Spectrum Disorders Children (APAUTRES) N/A
Enrolling by invitation NCT04100486 - Non-Invasive Bioelectronic Analytics